We found that aFP led to a significant increase AH1 specific CD8+ T cells per tumor weight in the aFP-treated groups (control vs. aFP, control vs. aFP + anti-PD-1, anti-PD-1 vs. aFP and anti-PD-1 vs. aFP + anti-PD-1 (p < 0.005); Fig. 2c). This evidence concerns the gene CD8A and neoplasm.